Related references
Note: Only part of the references are listed.Calcium-activated chloride channel is involved in the onset of diarrhea triggered by EGFR tyrosine kinase inhibitor treatment in rats
Yumi Harada et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Epidermal growth factor receptor inhibitor-induced diarrhea: clinical incidence, toxicological mechanism, and management
Gabriel Tao et al.
TOXICOLOGY RESEARCH (2021)
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
C. H. Barcenas et al.
ANNALS OF ONCOLOGY (2020)
Potentiation of calcium-activated chloride secretion and barrier dysfunction may underlie EGF receptor tyrosine kinase inhibitor-induced diarrhea
Younjoo Kim et al.
PHYSIOLOGICAL REPORTS (2020)
The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea
Hope S. Rugo et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea
Tianying Duan et al.
JCI INSIGHT (2019)
Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines
P. Bossi et al.
ANNALS OF ONCOLOGY (2018)
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
S. M. Swain et al.
ANNALS OF ONCOLOGY (2017)
HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens
Jennifer J. Gao et al.
CLINICAL BREAST CANCER (2017)
Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome
M. R. Blake et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Targeted therapy-induced diarrhea: A review of the literature
M. A. Pessi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors
V. Hirsh et al.
CURRENT ONCOLOGY (2014)
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
A. Schneeweiss et al.
ANNALS OF ONCOLOGY (2013)
Crofelemer: A Review of its Use in the Management of Non-Infectious Diarrhoea in Adult Patients with HIV/AIDS on Antiretroviral Therapy
James E. Frampton
DRUGS (2013)
Efficacy and Safety of Crofelemer for Noninfectious Diarrhea in HIV-Seropositive Individuals (ADVENT Trial): A Randomized, Double-Blind, Placebo-Controlled, Two-Stage Study
Rodger D. MacArthur et al.
HIV CLINICAL TRIALS (2013)
Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS
Twisha S. Patel et al.
HIV AIDS-RESEARCH AND PALLIATIVE CARE (2013)
Crofelemer for the treatment of secretory diarrhea
Jessica Cottreau et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2012)
Effects of quinidine on antinociception and pharmacokinetics of morphine in rats
Takashi Okura et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2010)
Crofelemer, an Antisecretory Antidiarrheal Proanthocyanidin Oligomer Extracted from Croton lechleri, Targets Two Distinct Intestinal Chloride Channels
Lukmanee Tradtrantip et al.
MOLECULAR PHARMACOLOGY (2010)
Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
Alexander Stein et al.
Therapeutic Advances in Medical Oncology (2009)
Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer
M Karthaus et al.
ONCOLOGY (2005)
A novel extract SB-300 from the stem bark latex of Croton lechleri inhibits CFTR-mediated chloride secretion in human colonic epithelial cells
H Fischer et al.
JOURNAL OF ETHNOPHARMACOLOGY (2004)
Share Paper
